Get started
Author

David Wong

Observed name: David C Wong
ORCID: 0000-0002-3571-6282
Observed ORCID: 0000-0002-3571-6282
OpenAlex ID: A5101918507
The use of 68Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy
2019 · Sheliyan Raveenthiran, John Yaxley, et al. · Prostate Cancer and Prostatic Diseases · 55
The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison
2021 · Arsalan Tariq, Michael Kwok, et al. · Urologic Oncology Seminars and Original Investigations · 35
Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT)
2022 · Arsalan Tariq, Stephen McGeorge, et al. · Urologic Oncology Seminars and Original Investigations · 18
Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics
2024 · Matthew J. Roberts, Nathan Papa, et al. · British Journal of Urology · 15
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort
2024 · Arsalan Tariq, Adam Pearce, et al. · European Urology Focus · 8
PDF
Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management
2023 · Shivanshan Pathmanathan, Arsalan Tariq, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 7
PDF
Histological findings of totally embedded robot assisted laparoscopic radical prostatectomy (RALP) specimens in 1197 men with a negative (low risk) preoperative multiparametric magnetic resonance imaging (mpMRI) prostate lobe and clinical implications
2020 · William John Yaxley, François-Xavier Nouhaud, et al. · Prostate Cancer and Prostatic Diseases · 7
Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
2021 · William John Yaxley, Rhiannon McBean, et al. · Korean journal of urology · 6
Multimodality Imaging to Diagnose Isolated Cardiac Sarcoidosis and Determine Regional Inflammatory Activity Levels
2017 · Kenneth Au, David Wong, et al. · CASE · 2
PDF
Transthyretin Cardiac Amyloidosis: A Noninvasive Multimodality Approach to Diagnosis Using Transthoracic Echocardiography, 99m-Tc-Labeled Phosphate Bone Scanning, and Cardiac Magnetic Resonance Imaging
2017 · Akhil Shukla, David Wong, et al. · CASE · 2
PDF
The value of post radiotherapy prostate specific antigen dynamics for prostate cancer risk stratification models
2025 · Jane Shortall, Eliana Vasquez Osorio, et al. · Physics and Imaging in Radiation Oncology · 1
PDF
Ctni-25. Multi-site, Prospective Trial Evaluating Fet-pet in Glioblastoma (fig) Study (trog 18.06): Central Nuclear Medicine and Radiation Oncology Review of Fet-pet Biologic Target Volume Delineation for Radiation Planning
2025 · Eng-Siew Koh, Roslyn J Francis, et al. · Neuro-Oncology
PDF
3511 External validation of Prostate Specific Antigen dynamics for prediction of biochemical recurrence with variable androgen deprivation therapy duration
2025 · Jane Shortall, Andrew Green, et al. · Radiotherapy and Oncology
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) compared to computed tomography (CT) for advanced renal cell carcinoma (RCC).
2022 · Shivanshan Pathmanathan, Arsalan Tariq, et al. · Journal of Clinical Oncology
X marks the spot
2003 · David C Wong · The Medical Journal of Australia
Works count: 15
Citation count: 156
H-index: 7
I10-index: 4
Year
Topic
Type